A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrlich, Dean, Jamaluddin, Nimah, Pisegna, Joseph, Padua, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832071/
https://www.ncbi.nlm.nih.gov/pubmed/29666723
http://dx.doi.org/10.1155/2018/9679287
_version_ 1783303256757239808
author Ehrlich, Dean
Jamaluddin, Nimah
Pisegna, Joseph
Padua, David
author_facet Ehrlich, Dean
Jamaluddin, Nimah
Pisegna, Joseph
Padua, David
author_sort Ehrlich, Dean
collection PubMed
description Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab.
format Online
Article
Text
id pubmed-5832071
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58320712018-04-17 A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis Ehrlich, Dean Jamaluddin, Nimah Pisegna, Joseph Padua, David Case Rep Gastrointest Med Case Report Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab. Hindawi 2018-02-15 /pmc/articles/PMC5832071/ /pubmed/29666723 http://dx.doi.org/10.1155/2018/9679287 Text en Copyright © 2018 Dean Ehrlich et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ehrlich, Dean
Jamaluddin, Nimah
Pisegna, Joseph
Padua, David
A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_full A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_fullStr A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_full_unstemmed A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_short A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_sort challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832071/
https://www.ncbi.nlm.nih.gov/pubmed/29666723
http://dx.doi.org/10.1155/2018/9679287
work_keys_str_mv AT ehrlichdean achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT jamaluddinnimah achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT pisegnajoseph achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT paduadavid achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT ehrlichdean challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT jamaluddinnimah challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT pisegnajoseph challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT paduadavid challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis

Ejemplares similares